Start Date
May 2, 2022
Primary Completion Date
July 25, 2022
Study Completion Date
November 30, 2022
Tozinameran
A single standard dose (30mcg) will be administered on day 0 of the study.
Elasomeran
A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
Tozinameran
A single standard dose (30mcg) will be administered on day 0 of the study.
Elasomeran
A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
Bivalent Pfizer-BioNTech
A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
Bivalent Moderna
A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg)will be administered on day 0 of the study.
Bivalent Pfizer-BioNTech
A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg) will be administered on day 0 of the study.
Bivalent Moderna
A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
Royal Children's Hospital, Murdoch Children's Research Institute, Melbourne
Lead Sponsor
Coalition for Epidemic Preparedness Innovations
OTHER
The Peter Doherty Institute for Infection and Immunity
OTHER
Murdoch Childrens Research Institute
OTHER